| Einhäupl et al 1991, intravenous heparin versus placebo | |||
| Heparin versus placebo | Outcome at three months | ||
| Heparin group (n = 10) | |||
| Total recovery | 8 patients | ||
| Residual motor deficit | 2 patients | ||
| Placebo group (n = 10) | |||
| Total recovery | 1 patient | ||
| Minor residual deficit | 6 patients | ||
| Deaths | 3 patients | ||
| De Bruijn and Stam 1999, subcutaneous nadroparin versus placebo | |||
| Outcome difference | Nadroparin (n = 30) | Placebo (n = 29) | Risk difference |
| At three weeks | |||
| Deaths | 2 | 4 | |
| BI score <15 | 4 | 3 | |
| Death or BI <15 | 6 (20 percent) | 7 (24 percent) | 4 percent (95% CI, –25 to 17 percent) |
| At 12 weeks | |||
| Deaths | 2 | 4 | |
| Dependent (OHS 3 to 5) | 2 | 2 | |
| Death or dependent | 4 (13 percent) | 6 (21 percent) | 7 percent (95% CI, –26 to 12 percent) |
